The Edwards SAPIEN 3 Ultra valve sits in a gleaming stainless-steel tray, its cobalt-chromium frame catching the overhead OR lights as a nurse wheels it toward a catheterization lab in a US hospital.

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

The SAPIEN 3 Ultra brings a lower-profile transcatheter heart valve and a refined delivery system for severe aortic stenosis patients who are too high-risk for open surgery. This bestseller drives the ...

Last month, Edwards Lifesciences recalled its SAPIEN 3 Ultra Delivery System after reports of burst balloons during implantation, resulting in significant difficulty retrieving the valve into the ...

Edwards Lifesciences could benefit from broader Medicare eligibility for TAVR, including coverage for patients with asymptomatic severe aortic stenosis.